A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Relapsed/Refractory Peripheral T Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing Municipality, China
Contact: Study coordinator (Zhao Wang professor, postdoctor) · wangzhao@ccmu.edu.com · 010-63138585

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Guangzhou, China

Registry of Older Patients With Cancer

Chronic Myeloproliferative Disorders · Cognitive/Functional Effects · Leukemia

Abroad (travel likely)Recruiting

Boone, United States · Chapel Hill, United States

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

T Cell Lymphoma · T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

New Haven, United States · New York, United States

Evaluate the Safety and Clinical Activity of HH2853

FL Lymphoma · Epithelioid Sarcoma · Peripheral T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Jacksonville, United States